Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.64 |
| ▸ | CTSB | P07858 | 3/20 | 0.63 |
| ▸ | GRB2 | P62993 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14682322 | 1.00 | CAPN1 (0.64) | CAPN1CTSBGRB2OPRM1DPP4 | |
| SCHEMBL20958599 | 1.00 | CAPN1 (0.64) | CAPN1CTSBGRB2OPRM1DPP4 | |
| SCHEMBL14672864 | 1.00 | CAPN1 (0.64) | CAPN1CTSBGRB2OPRM1DPP4 | |
| SCHEMBL14728349 | 0.94 | CAPN1 (0.57) | CAPN1CTSBGRB2OPRM1DPP4 | |
| SCHEMBL14682287 | 0.91 | CAPN1 (0.54) | CAPN1CTSBGRB2OPRM1DPP4 | |
| SCHEMBL21549054 | 0.91 | CAPN1 (0.54) | CAPN1CTSBGRB2OPRM1DPP4 | |
| SCHEMBL14682326 | 0.90 | CAPN1 (0.65) | CAPN1CTSBGRB2OPRM1 | |
| SCHEMBL16488744 | 0.90 | CAPN1 (0.65) | CAPN1CTSBGRB2OPRM1 | |
| SCHEMBL19492652 | 0.90 | CAPN1 (0.62) | CAPN1CTSBGRB2OPRM1 | |
| SCHEMBL28630988 | 0.89 | CAPN1 (0.53) | CAPN1CTSBGRB2OPRM1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180325893-A1 | SUBACUTE ADMINISTRATION OF NMDA MODULATORS ALONE OR IN COMBINATION | UNIV NORTHWESTERN (US) | 2018-11-15 | — | — | US | claimed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2019-05-09 | — | — | US | disclosed |
| US-20180325893-A1 | SUBACUTE ADMINISTRATION OF NMDA MODULATORS ALONE OR IN COMBINATION | UNIV NORTHWESTERN (US) | 2018-11-15 | — | — | US | disclosed |
| EP-2771021-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTH WESTERN UNIV (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180237474-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2018-08-23 | — | — | US | disclosed |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| US-8673843-B2 | NMDA receptors modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | OPRL1, GRIN2A, GRM1 | CAPN1 1425/4885CTSB 4054/4885GRB2 1267/4885 |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CAPN1 866/4885CTSB 4049/4885GRB2 2341/4885 |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CAPN1 866/4885CTSB 4049/4885GRB2 2341/4885 |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CAPN1 866/4885CTSB 4049/4885GRB2 2341/4885 |
| US-20180325893-A1 | SUBACUTE ADMINISTRATION OF NMDA MODULATORS ALONE OR IN COMBINATION | GRIN2A, GRIN2D, GRIN1 | CAPN1 1805/4885CTSB 2574/4885GRB2 2182/4885 |
| US-20180237474-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CAPN1 866/4885CTSB 4049/4885GRB2 2341/4885 |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CAPN1 902/4885CTSB 4087/4885GRB2 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.